CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 106 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $152 | -63.5% | 17,468 | -73.7% | 0.02% | -71.2% |
Q4 2022 | $416 | -99.9% | 66,329 | -33.0% | 0.05% | +13.0% |
Q3 2022 | $347,000 | +89.6% | 99,029 | +59.2% | 0.05% | +70.4% |
Q2 2022 | $183,000 | -69.4% | 62,194 | -67.6% | 0.03% | -66.2% |
Q1 2022 | $598,000 | -23.1% | 192,244 | -16.5% | 0.08% | -18.4% |
Q4 2021 | $778,000 | -19.3% | 230,258 | -12.9% | 0.10% | 0.0% |
Q3 2021 | $964,000 | +69.1% | 264,224 | +102.2% | 0.10% | +53.1% |
Q2 2021 | $570,000 | -32.6% | 130,672 | -29.9% | 0.06% | -54.3% |
Q1 2021 | $846,000 | -3.5% | 186,317 | +21.9% | 0.14% | -2.1% |
Q4 2020 | $877,000 | +126.6% | 152,797 | -22.6% | 0.14% | +217.8% |
Q4 2019 | $387,000 | +64.0% | 197,290 | +327.9% | 0.04% | +40.6% |
Q3 2019 | $236,000 | -22.1% | 46,103 | +9.0% | 0.03% | -5.9% |
Q2 2019 | $303,000 | -56.3% | 42,285 | -32.3% | 0.03% | -10.5% |
Q3 2018 | $693,000 | +13.8% | 62,500 | -5.6% | 0.04% | +2.7% |
Q4 2017 | $609,000 | -50.0% | 66,200 | -56.2% | 0.04% | -55.4% |
Q3 2017 | $1,218,000 | – | 151,100 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |